Business Context and Reporting Period
This Form 8-K Current Report is filed by Oramed Pharmaceuticals Inc. for the reporting period ending February 28, 2011. The filing details a material definitive agreement entered into on February 22, 2011, involving the Company's wholly-owned subsidiary, Oramed Ltd., and D.N.A Biomedical Solutions Ltd. ("D.N.A"). The transaction concerns the restructuring of the joint venture Entera Bio Ltd. ("Entera") and includes a concurrent capital raise.
Key Financial Metrics and Transaction Values
The filing outlines specific financial terms for the proposed transactions but does not provide consolidated revenue, profit, or cash flow statements for the Company.
- Sale of Entera Stake: Oramed Ltd. will sell 47% of Entera's outstanding share capital to D.N.A.
- Consideration for Entera Sale:
- Promissory note: $450,000 principal at 0.45% annual interest, payable within four months.
- Equity: 8,404,667 ordinary shares of D.N.A with an aggregate market value of approximately $700,000.
- Capital Raise (Securities Purchase Agreement):
- Total purchase price: $250,000 in cash.
- Issuance: 781,250 shares of Oramed common stock and warrants to purchase up to 273,438 shares.
- Unit Price: $0.32 per unit (one share + warrant for 0.35 shares).
- Warrant Terms: Exercise price of $0.50 per share; five-year term.
- Patent Royalties: Oramed Ltd. will receive 3% of Entera's net revenues on the assigned patent.
Material Changes and Transaction Structure
The filing reports a significant change in the ownership structure of Entera Bio Ltd. and the Company's capital base:
- Joint Venture Restructuring: Upon closing, the existing 50/50 Joint Venture Agreement between Oramed Ltd. and D.N.A regarding Entera will be terminated. Oramed Ltd. will reduce its stake in Entera from 50% to 3% (retaining a 3% stake after selling 47% of the total capital, assuming the 50% holding represents the total capital base prior to the sale).
- Patent Transfer: Oramed Ltd. will assign all rights to a specific patent (licensed to Entera since August 2010) to Entera. Oramed retains a license back for use in diabetes and influenza applications.
- Related Party Transaction: Mr. Zeev Bronfeld, a director and controlling shareholder of D.N.A, holds approximately 9.12% of Oramed's outstanding share capital. Consequently, the transaction requires approval from D.N.A's shareholders under Israeli law.
Outlook, Risks, and Contingencies
Closing Conditions and Timeline:
- Closing is scheduled for the first business day following the satisfaction of all conditions.
- Termination Right: If closing does not occur by March 31, 2011, the Company reserves the right to terminate the agreements.
- Regulatory Approval: Closing is contingent upon D.N.A shareholder approval due to the related party nature of the transaction.
Management Commentary: The Company issued a press release on February 28, 2011, announcing these transactions. The assigned technology differs from the Company's primary oral insulin delivery technology.
Investor Verification Checklist
- Verify the closing date and confirmation that all conditions, including D.N.A shareholder approval, have been met.
- Confirm the receipt of the $250,000 cash proceeds from the securities purchase agreement.
- Monitor the valuation of the 8,404,667 D.N.A shares received as consideration, as market value may fluctuate.
- Review the specific definitions of "net revenues" in the Patent Transfer Agreement to assess the potential value of the 3% royalty stream.
- Check for any subsequent filings regarding the termination of the agreements if the March 31, 2011 deadline is not met.